Aberrant MET activation occurs in many human cancers, correlates with poor prognosis, and is considered an important candidate for targeted therapy (Kaposi-Novak et al, 2006; Comoglio et al, 2008; Liu et al, 2008). This evidence concerns the gene MET and cancer.